Back to Browse Journals » Journal of Blood Medicine » Volume 1

A review of immune thrombocytopenic purpura: focus on the novel thrombopoietin agonists

Authors Meaghan Khan, Joseph Mikhael

Published Date March 2010 Volume 2010:1 Pages 21—31

DOI http://dx.doi.org/10.2147/JBM.S6803

Published 23 March 2010

Meaghan Khan, Joseph Mikhael

Division of Hematology – Oncology, Scottsdale, AZ, USA

Abstract: Immune thrombocytopenic purpura (ITP) is an autoimmune disorder that is characterized by antibody-mediated platelet destruction and decreased platelet production. ITP and its treatments have been recognized to cause diminished quality of life in those afflicted with this illness on levels comparable to other chronic diseases. The disease can be self-limiting, but in adults it often is a chronic process requiring medical intervention to maintain appropriate platelet counts and to reduce bleeding events. Many patients go on to develop disease that is refractory to current interventions. Historically, the aim of treatment has been focused on reducing the amount of antibody-mediated destruction but newer therapies have centered on the decreased platelet production. Two new medications that target production of platelets have recently been USA, Food and Drug Administration (FDA) approved for the treatment of chronic relapsing ITP. Here, we provide an overview of ITP and a comprehensive review of the newest therapies aimed at the stimulation of platelet production.

Keywords: immune thrombocytopenic purpura, therapy, thrombopoietin, romiplostim, AMG 531, eltrombopag

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies

Jorge Castillo, Kimberly Perez

Journal of Blood Medicine 2010, 1:1-8

Published Date: 25 February 2010

Venous thromboembolism and pregnancy

Maristella D’Uva, Pierpaolo Di Micco, Ida Strina, et al

Journal of Blood Medicine 2010, 1:9-12

Published Date: 3 March 2010

Homeostatic and pathogenic extramedullary hematopoiesis

Chang H Kim

Journal of Blood Medicine 2010, 1:13-19

Published Date: 23 March 2010

Treatment of hemophilia: a review of current advances and ongoing issues

Antonio Coppola, Mirko Di Capua, Matteo Nicola Dario, et al.

Journal of Blood Medicine 2010, 1:183-195

Published Date: 30 August 2010

Deep vein thrombosis: a clinical review

Kesieme EB, Kesieme CN, Jebbin N, Irekpita E, Dongo A

Journal of Blood Medicine 2011, 2:59-69

Published Date: 29 April 2011

Quantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal growth factor receptor in breast cancer tissue arrays

Yang XQ, Chen C, Peng CW, Hou JX, Liu SP, Qi CB, Gong YP, Zhu XB, Pang DW, Li Y

International Journal of Nanomedicine 2011, 6:2265-2273

Published Date: 11 October 2011

Nanofibrous poly(lactide-co-glycolide) membranes loaded with diamond nanoparticles as promising substrates for bone tissue engineering

Parizek M, Douglas TEL, Novotna K, Kromka A, Brady MA, Renzing A, Voss E, Jarosova M, Palatinus L, Tesarek P, Ryparova P, Lisa V, dos Santos AM, Bacakova L

International Journal of Nanomedicine 2012, 7:1931-1951

Published Date: 17 April 2012

Newer agents in antiplatelet therapy: a review

Yeung J, Holinstat M

Journal of Blood Medicine 2012, 3:33-42

Published Date: 25 June 2012